RenovoRx Inc. Common Stock RNXT · Stock Open RenovoRx Inc. Common Stock in new tab
RenovoRx Inc. Common Stock Analysis (RNXT)
Is RenovoRx Inc. Common Stock a good investment? RenovoRx Inc. Common Stock (RNXT) is currently trading at 1.67 USD. Market analysts have a consensus price target of 7.13 USD. This suggests a potential upside from current levels.
Earnings Schedule: RenovoRx Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.12.
Investor FAQ
Does RenovoRx Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is RenovoRx Inc. Common Stock?
RenovoRx Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.31.
Company Profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Community Discussion